Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles, Alasdair; Cohen, Jeffrey A; Fox, Edward J; Giovannoni, Gavin; Hartung, Hans-Peter; Havrdova, Eva; Schippling, Sven; Selmaj, Krzysztof W; Traboulsee, Anthony; Compston, Alastair; Margolin, David H; Thangavelu, Karthinathan; Chirieac, Madalina C; Jody, Darlene; Xenopoulos, Panos; Hogan, Richard J; Panzara, Michael A; Arnold, Douglas L; CARE-MS II and CAMMS03409 Investigators,

View / Open Files

Published version (PDF, 778Kb)

Authors

Coles, Alasdair

Cohen, Jeffrey A

Fox, Edward J

Giovannoni, Gavin

Hartung, Hans-Peter

Havrdova, Eva

Schippling, Sven

Publication Date

2017-09

Journal Title

Neurology

ISSN

0028-3878

Volume

Issue

Pages

1117-1126

Language

eng

Type

Article

This Version

VoR

Physical Medium

Print-Electronic

Metadata

Show full item record

Citation

Coles, A., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H., Havrdova, E., Schippling, S., et al. (2017). Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.. Neurology, 89 (11), 1117-1126. https://doi.org/10.1212/wnl.0000000000004354

Keywords

CARE-MS II and CAMMS03409 Investigators, Brain, Humans, Multiple Sclerosis, Relapsing-Remitting, Atrophy, Immunologic Factors, Disability Evaluation, Organ Size, Treatment Outcome, Follow-Up Studies, Time Factors, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Alemtuzumab

Identifiers

External DOI: https://doi.org/10.1212/wnl.0000000000004354

This record's URL: https://www.repository.cam.ac.uk/handle/1810/270149

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

Licence URL: http://creativecommons.org/licenses/by-nc-nd/4.0/

The following licence files are associated with this item:

Creative Commons

Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International